| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
dcang84
Veteran |
24-Jan-2008 12:37
|
|
x 0
x 0 Alert Admin |
In the next 180 days, u can expect the new CEO to impress with numbers or give a forward looking outlook. If all else fails, you can expect the company to raise capital through a rights issue at some point. I must reiterate to those who are still not vested that this is a highly speculative counter. Take it with a pinch of salt. If that doesn't work use a table spoon. |
| Useful To Me Not Useful To Me | |
|
PinkyGoh
Member |
24-Jan-2008 12:28
|
|
x 0
x 0 Alert Admin |
since investing in BIG in Sep last year, I found technical analysis, financial analysis etc doesn't work for this share. This is a share which didn't have good financial track record, but have not started showing the value of its potential. It had shown the potential, now is turning the potential into $ and cents, then you will see the share price going up. If you're one who invest based on analysis using historical data, you will never be convinced to buy....my 2 cents worth of thoughts. |
| Useful To Me Not Useful To Me | |
|
|
|
|
limhpp
Veteran |
24-Jan-2008 10:36
|
|
x 0
x 0 Alert Admin |
No doubt about it, Bengster is a good guy who share valuable informations to all forumers. My question is only purely TA. I am just seeking advise from expert TA... nothing else. Still learning. 
|
| Useful To Me Not Useful To Me | |
|
ekekeg
Veteran |
24-Jan-2008 10:15
|
|
x 0
x 0 Alert Admin |
Correct me if I'm wrong. As retail investors in whatever counters we are investing be it BIG or any other company, we do need people like Bengster who not only are big timeplayers but also unselfish by giving us good knowledge of news they came across or research and analysis they are doing. Bengster has been doing that. We must continue to hope for people like Bengster to post for our knowlege and advantage. At least if we are bothered by some matters with a company, we have strength to make noises that can be heard at AGMs. And if we found some good people among us who have substantial holdings in the company that we are vested, our expectations of the company can be much easier be voiced or even achieved by such strength at AGMs or even EGMs.. Just thinking loud. |
| Useful To Me Not Useful To Me | |
|
limhpp
Veteran |
24-Jan-2008 09:33
|
|
x 0
x 0 Alert Admin |
cashiertan, Don't forget there is also a gap not fully filled just after chirstmas day. Will it? Need your expertise please?
|
| Useful To Me Not Useful To Me | |
|
|
|
|
gbleng
Member |
24-Jan-2008 09:13
|
|
x 0
x 0 Alert Admin |
Poise for the next level of growth... |
| Useful To Me Not Useful To Me | |
|
PinkyGoh
Member |
24-Jan-2008 08:46
|
|
x 0
x 0 Alert Admin |
appointment of Mr Robert Michael Kleine as a Director and President & Chief Executive Officer of the Company with effect from 24 January 2008. Good, bad or neutral news??? |
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
24-Jan-2008 04:03
|
|
x 0
x 0 Alert Admin |
i dunnoe how to trade biosensor based on wed chart. need tomolo to see how it can be traded. how many think it can cover the gap tomolo to 90c? |
| Useful To Me Not Useful To Me | |
|
|
|
|
superbad2
Member |
24-Jan-2008 01:08
|
|
x 0
x 0 Alert Admin |
opportunity to collect at below 80 cents soon. |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
23-Jan-2008 23:37
|
|
x 0
x 0 Alert Admin |
Im standing in the same line as all the long term shareholders and all forumers that are vested in BIG. Whether vested heavily or slightly vested is still our money and we have to be very serious about it. I try to share as much as i know. Here is another post about ABT on takeover possibilty of BIG. ABT is not so desperate as JNJ but they are also worried if JNJ buys over BIG. ABT's ABSORB DES program is breaching BIG's patent of "any limus drug on biodegredable polymer". But if ABT buys over BIG, they will be the undisputed DES leader in this industry. From nothing just 2 years back to to number one. (Pls refer to my post on why ABT is a very possible buyer of BIG posted about a month ago) Abbott says to slow acquisition paceNEW YORK, Jan 23 (Reuters) - The chief executive officer of Abbott Laboratories Inc (ABT.N: Quote, Profile, Research) on Wednesday said the healthcare company is not currently considering any major acquisitions, and noted the company's pace of deal-making will likely slow in the coming decade. "We don't have on the radar screen a significant target," Miles White told investors on a conference call after the suburban Chicago company reported fourth-quarter earnings in line with Wall Street expectations. "Don't look for the next 10 years to be like the last 10," White said, referring to Abbott's slowing pace of acquisitions. One of the company's most noted acquisitions in recent years was its purchase of the vascular business of Guidant Corp, which included a promising stent called Xience that Abbott expects to become a big seller. White said Abbott will selectively remain on the hunt for "opportunistic" deals that would bring the company products that fit in with its current portfolio. |
| Useful To Me Not Useful To Me | |
|
jackjames
Elite |
23-Jan-2008 23:29
|
|
x 0
x 0 Alert Admin |
ha ha hah a... you ar... beh tahan.. |
| Useful To Me Not Useful To Me | |
|
Alligator
Veteran |
23-Jan-2008 23:25
Yells: "learning from past " |
|
x 0
x 0 Alert Admin |
wa pian, jackjames, once upon a time a peanut is about 600K, wow, if you own one peanut that was very very nice lah.. |
| Useful To Me Not Useful To Me | |
|
|
|
|
jackjames
Elite |
23-Jan-2008 23:22
|
|
x 0
x 0 Alert Admin |
bengster88, I really wonder who u are, you sound like Ben....... from the US, hee.. 700 lots purchased is not a joke, that's 560K, a condo price ! waaa.... you make us look like peanuts u know, heee... |
| Useful To Me Not Useful To Me | |
|
Manikamaniho
Senior |
23-Jan-2008 23:21
|
|
x 0
x 0 Alert Admin |
I agree with that... This stock does seems to have a life of its own... 
|
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
23-Jan-2008 23:18
|
|
x 0
x 0 Alert Admin |
Event driven stock. Fundamentally unappreciated. TA may not make much sense. UK NICE to totally cut DES subsidy was raised a few months ago. I think the health care subsidy programme there could be facing financial strains and they are finding ways to cut subsidies. Since DES and BMS price difference by a few times, DES will be a target. However i feel it is unfair as they are basing DES performance on first generation (namely Cypher and Taxus). If we compare Biomatrix VS Taxus, obviously the 2 DESs are of totally different class. How can they lump both together as same category? Frankly even if you were to give me a 100% totally subsidised Taxus DES for implant, sorry i would rather pay for Biomatrix out from my own pocket. I feel they should compare clinical results and compare cost benefit analysis of all the brands of DESs instead of lumping them all together. If DES subsidy is cut, most likely DES price may have to be lowered by around 10 to 15% to make them more affordable. So i would say this is not so good news for BIG. In fact, the other European countries may follow UK's footsteps which may led to more DES price cuts in those european countries that change their DES subsidy program. As for takeover analysis, i have been monitoring all the possible cnadidates. I think the most likely candidate will still be JNJ, with a very high chance of it happening in 2008. Second most likely candidate will be Abbott. I have also considered Terumo as a likely candidate but concluded that Terumo is too small to do this takeover deal. A takeover of BIG will cost around US$2.5B. Terumo is the largest Japanese medical device company with annual sales of around US$2.5B and market cap of around US$10B. BIG shareholders like you and me always prefer all cash takeover. Terumo can only afford do a part cash part share swap deal. Leverage Buyout (LBO) by Terumo by partnering a large fund is not possible as BIG do not have stable strong cash flow profits to meet interest payments of the LBO. Anyway, BIG was never a candidate for LBO. Plus, there is credit crunch in LBO industry. Also, Terumo may not be well connected in USA (largest DES market with 40% of global DES sales) for smooth FDA approval and sales channel in USA. To maximise benefit of taking over BIG, the buyer has to make the best use of BIG's assets (top class DES technology and patents) to capture the all important USA DES market. BSX is out also because they have their own financial problems to settle after the costly Guidant takeover which i think is a mistake. I think Medtronic is still non-believer of biodegredable polymer. But they will serious start to look into taking over BIG when their Endeavor DES start to have late-thrombosis problem which i think most likely will happen. A durable polymer is still a durable polymer after all and will have durable polymer problems like late-thrombosis. In summary, 2 most possible candidates now: JNJ and ABT but most likely it will be JNJ. Takeover could be any moment, anytime in 2008. BIG is already a ripe fruit waiting to be plucked. |
| Useful To Me Not Useful To Me | |
|
Maxximo
Member |
23-Jan-2008 23:11
|
|
x 0
x 0 Alert Admin |
BIG may cover gap at 0.74 if mkt bad news still flow.... a good entry if it does touches here, me will go in grab somemore to increase my long term holding in BIG .... Cheers to all .... |
| Useful To Me Not Useful To Me | |
|
singaporegal
Supreme |
23-Jan-2008 22:30
Yells: "Female TA nut" |
|
x 0
x 0 Alert Admin |
No offense taken. I saw the charts for this 1-2 months ago and it made no sense to me. That was why I stayed away. Once in a while I will come back to see if the counter adheres to certain charts that I use. But unfortunately, this counter doesn't. |
| Useful To Me Not Useful To Me | |
|
novena_33
Veteran |
23-Jan-2008 22:28
|
|
x 0
x 0 Alert Admin |
by now u should know not too follow this base on chart....... sorry no offends for this.... |
| Useful To Me Not Useful To Me | |
|
singaporegal
Supreme |
23-Jan-2008 22:24
Yells: "Female TA nut" |
|
x 0
x 0 Alert Admin |
TA charts for this counter are really really crazy.... I don't dare to play with this one... |
| Useful To Me Not Useful To Me | |
|
clauswu
Member |
23-Jan-2008 20:58
|
|
x 0
x 0 Alert Admin |
Found this posting on Reuters - wonder how it might impact BIG's share price next week? Any comments? UK agency stent decision now set for next weekLONDON (Reuters) - Britain's medicines advisory agency is now planning to publish its latest recommendations on the cost-effectiveness of drug-coated stents late next week, in a decision that could draw fire from manufacturers. A spokesman for the National Institute for Health and Clinical Excellence (NICE) said on Wednesday the announcement is scheduled for late in the week beginning January 28. The decision, which had been expected before then, will be published on the agency's Web site. Drug-coated versions of stents -- tiny, wire-mesh tubes used to prop open clogged arteries -- are a multibillion-dollar global business for companies like Boston Scientific, Johnson & Johnson, Medtronic and Abbott Laboratories. But their use has fallen sharply in the past year or so on concerns they may sometimes cause blood clots. NICE caused a storm last August when its initial assessment concluded that drug-eluting stents were not worth the money when compared with older bare-metal ones. The difference in price is around 600 pounds ($1,175). Morgan Stanley analysts have said companies could potentially offer price concessions to keep drug stents in use on Britain's state health service but would have to decide whether price cuts were commercially viable. Since 1999, NICE has led the world in measuring the cost-effectiveness of new treatments. Other governments and insurers closely watch the agency's actions, particularly in Europe. Morgan Stanley said it was possible the NICE recommendation could lead to a 13-15 percent European price cut, reducing the size of the market by $102 million, or 5 percent in 2008, by $173 million in 2009 and $251 million in 2010. |
| Useful To Me Not Useful To Me | |
